Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Study sponsor: Axsome Therapeutics, Inc. · AXSM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-06-30Estimated
Enrollment · participants468Estimated
Source updated2026-11-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.